Akèy › Kansè pankreyas › Massachusetts › Boston
Etid klinik pou Kansè pankreyas nan Boston, MA
43 etid pou Kansè pankreyas ap chèche patisipan nan sit nan ak bò kote Boston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, Boston
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
Ap rekriteFaz 1
- Dana-Farber Cancer Institute, Boston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Ap rekriteFaz 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
Ap rekrite
- Dana-Farber Cancer Institute, Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Ap rekriteFaz 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of PHN-012 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- PHN-012-001 Site, Boston
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Ap rekriteFaz 3
- Dana Farber Cancer Institute, Boston
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Ap rekriteFaz 3
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute (DFCI), Boston
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Ap rekriteFaz 3
- Investigative Site US022, Boston
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
Ap rekriteEtid obsèvasyon
- Dana-Farber Cancer Institute, Boston
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Ap rekriteFaz 1/2
- Massachusetts General Hospital - Main Campus, Boston
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Ap rekriteFaz 1
- Dana-Farber Cancer Institute, Boston
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Ap rekriteFaz 2
- Local Institution - 0124, Boston
Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
Ap rekriteEtid obsèvasyon
- Boston Children's Hospital, Boston
Resilience and Equity in Aging, Cancer, and Health (REACH)
Ap rekrite
- Dana-Farber Cancer Institute, Boston
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Ap rekriteFaz 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Pancreatic Cancer Early Detection Consortium
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Massachusetts General Hospital, Boston
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
Ap rekriteFaz 1
- Dana-Farber/Massachusetts General Hospital, Inc, Boston
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Ap rekriteFaz 1
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Ap rekriteFaz 1
- Research Site, Boston
- Research Site, Boston
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Ap rekriteFaz 1
- Dana Farber Cancer Institute, Boston
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
Ap rekriteFaz 1 bonèVolontè an sante akeyi
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Video Education With Result Dependent dIsclosure
Ap rekrite
- Dana Farber Cancer Institute, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
A Study of MGC028 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Mass General Brigham, Boston
- Dana Farber/Harvard Cancer Center, Boston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
Ap rekriteFaz 2
- Beth Israel Deaconess Medical Center - Division of Hematology/Oncology, Boston
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Ap rekriteFaz 1/2
- Dana-Farber Cancer Institute, Boston
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
Ap rekriteFaz 2
- Massachusetts General Hospital, Boston
Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial
Ap rekrite
- Dana Farber Cancer Institute, Boston
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Ap rekriteFaz 2
- Ohio State University-Telemedicine, Boston
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
Ap rekriteFaz 3
- Beth Israel Deaconess Medical Center, Boston
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
Stereotactic Magnetic Resonance Guided Radiation Therapy
Ap rekrite
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
The Cancer of the Pancreas Screening-5 CAPS5)Study
Ap rekriteFaz 3
- Dana Farber Cancer Center, Harvard University, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions
Ap rekriteEtid obsèvasyon
- Beth Israel Deaconess Medical Center, Boston
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Ap rekriteFaz 1
- Dana Farber/Partners Cancer Care Inc, Boston
Etid Kansè pankreyas nan lòt vil
- Houston, TX61 etid
- New York City, NY60 etid
- Nashville, TN39 etid
- Los Angeles, CA35 etid
- St. Louis, MO33 etid
- Arlington, VA33 etid
- Baltimore, MD31 etid
- San Antonio, TX31 etid
- Philadelphia, PA26 etid
- Tampa, FL26 etid
- Durham, NC24 etid
- San Diego, CA24 etid
Lòt etid nan Boston
- Kansè nan tete112 etid
- Kansè Poumon ki pa ti selil90 etid
- Kansè (tout kalite)85 etid
- Kansè Metastatik63 etid
- Kansè kolorektal63 etid
- Kansè poumon62 etid
- Kansè ovè61 etid
- Kansè pwostat59 etid
- Depresyon52 etid
- Kansè Endomèt50 etid
- Ensifizyans kadyak44 etid
- Leksemi mieloïd egi44 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.